California's CalRx initiative, launched by Gov. Gavin Newsom in 2020 as a state-run prescription drug label, can't fix the real problem driving high medication costs—a patent system exploited by brand-name pharmaceutical companies to block cheaper generics, according to an analysis published June 12, 2026 by Wayne T. Brough at the R Street Institute. While CalRx has brought some lower-cost medications to market, including insulin pens now available for $11 each, the commentary argues that "this public intervention into the pharmaceutical market only expands government interference without addressing the root cause of high drug prices." The state-run company faces the same patent barriers that plague private generic manufacturers, limiting its impact to a narrow slice of older drugs whose patents have already expired.
CalRx products already on shelves include a low-cost nasal spray version of naloxone—generic Narcan—for opioid overdoses, and the state recently provided $50 million in funding to nonprofit manufacturer Civica for insulin pens sold at $55 for a five-pack. But the three major insulin makers—Eli Lilly, Novo Nordisk, and Sanofi—slashed their own insulin prices by 75% shortly after, responding to federal Medicare changes under President Biden's Inflation Reduction Act, not to CalRx competition. Generic drugs now fill 90% of U.S. prescriptions while accounting for just 12% of drug spending, generating $467 billion in savings in 2024 alone. When three to five generics enter the market, prices fall 15% to 40%, and as much as 90% once 10 or more competitors arrive. Before the 1984 Hatch-Waxman Act launched the modern generic industry, generics held just a 13% market share.
According to the analysis, brand-name pharmaceutical companies exploit the patent system by creating what's commonly called a "thicket" of secondary patents covering formulation, dosage, and delivery devices—not just the active ingredient. The report cites Humira, a popular anti-inflammatory drug, which received 132 patents, a wall that kept the generic version available in Europe five years earlier than in the United States. Companies also engage in "product hops," marketing reformulated versions of a drug to shift the market before generics arrive and earn fresh patent protection. AstraZeneca's move from Prilosec to Nexium included a $500 million marketing blitz, and studies found "little real difference" between the two drugs, but the new patent effectively kept generics at bay while continuing monopoly profits.
The commentary explains that CalRx can do little to affect prices of new blockbuster drugs like GLP-1s for weight loss, targeted cancer treatments, or advanced gene therapies treating conditions from congenital blindness to sickle cell disease, because these medications remain under patent protection. The real barrier isn't a shortage of generic manufacturers—it's that brand-name companies use patent thickets, product hops, and lawsuits to stifle competition, creating roadblocks with roots going back 40 years to the Hatch-Waxman Act. While that legislation was "a success by all measures" in launching the generic industry, pharmaceutical companies have learned to game the system. California's nearly 1 million residents who travel to Mexico each year for more affordable medical care and prescription drugs won't find relief from a state-run label that faces the same legal obstacles as private competitors.
The analysis points to the bipartisan Eliminating Thickets to Increase Competition (ETHIC) Act, co-sponsored by California Rep. Darrell Issa, as the necessary solution. The proposed legislation would limit the number of related patents a brand-name company can assert against a single generic in an infringement lawsuit, making it cheaper and faster for generic providers to challenge patent thickets and reach the market. "Affordable medicine is important for Californians and all Americans, but only Congress can address these particular issues," the commentary concludes. A state-run drug company may help the uninsured and those with high deductibles access older medications, but without federal action to prune patent thickets and curb endless litigation, lower-cost drugs will continue sitting on the sidelines while brand manufacturers collect monopoly profits.